These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18537758)

  • 21. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
    Chan DC; Barrett PH; Watts GF
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrates after the FIELD study: Some answers, more questions.
    Wierzbicki AS
    Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
    Negi S; Ballantyne CM
    J Clin Lipidol; 2010; 4(5):365-70. PubMed ID: 21122680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical recommendations for the management of hyperlipidemia.
    Fischer S; Schatz U; Julius U
    Atheroscler Suppl; 2015 May; 18():194-8. PubMed ID: 25936326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R; Rumana U
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.
    Szapary PO; Rader DJ
    Curr Opin Pharmacol; 2001 Apr; 1(2):113-20. PubMed ID: 11714084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
    Borow KM; Nelson JR; Mason RP
    Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertriglyceridemia and cardiovascular risk reduction.
    Jacobson TA; Miller M; Schaefer EJ
    Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple.
    Vincent J
    Clin Pharmacol Ther; 2018 Aug; 104(2):220-224. PubMed ID: 30117592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
    Robins SJ
    Curr Opin Lipidol; 2003 Dec; 14(6):575-83. PubMed ID: 14624134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
    Hernández-Mijares A; Ascaso JF; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X; Millán J;
    Clin Investig Arterioscler; 2019; 31(2):75-88. PubMed ID: 30262442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid pharmacotherapy for treatment of atherosclerosis.
    Nicholls SJ; Pisaniello AD; Kataoka Y; Puri R
    Expert Opin Pharmacother; 2014 Jun; 15(8):1119-25. PubMed ID: 24702590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits and risks of the treatment with fibrates--a comprehensive summary.
    Okopień B; Bułdak Ł; Bołdys A
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
    Hausenloy DJ; Yellon DM
    Curr Opin Cardiol; 2009 Sep; 24(5):473-82. PubMed ID: 19574922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.
    Standl E
    Diab Vasc Dis Res; 2013 Mar; 10(2):99-114. PubMed ID: 22718811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.